Literature DB >> 21485600

Bacteriology and antibiotic susceptibility pattern of peritonsillar abscess.

A Acharya1, R Gurung, B Khanal, A Ghimire.   

Abstract

INTRODUCTION: Peritonsillar abscess is a common complication of acute tonsillitis. Its management consists of aspiration or surgical drainage followed by appropriate antibiotics. Appropriate antibiotic treatment depends on the common organisms associated with infection and their antibiotic sensitivity pattern in local scenario.
METHODS: Pus samples aspirated from diagnosed cases of peritonsillar abscess and submitted for culture and sensitivity in last two years were included in this study. Identification of different microorganisms was made on the basis of the microscopic findings, observation of their colony morphology and standard biochemical reactions. Susceptibility pattern to commonly used antibiotics were determined by Clinical Laboratory Standards Institute (CLSI) guidelines.
RESULTS: Altogether 24 pus samples were included in the study. Positive culture was obtained from 18 samples. Among them one organism was isolated from 13 samples whereas from five samples multiple organisms were isolated. From six samples no organisms could be cultured. Altogether Streptococcus pyogenes was isolated from 12 samples and Staphylococcus aureus from five samples. Other isolated organisms included Haemophlilus influenzae, Pseudomonas aeruginosa, Escherichia coli and Enterococcus species. Penicillin was effective for Streptococcus pyogenes whereas Staphylococcus aureus was resistant to it. Cloxacillin was found to be effective for Staphylococcus aureus. Ciprofloxacin and Ceftazidime were found to be effective for both organisms.
CONCLUSIONS: Streptococcus pyogenes and Staphylococcus aureus were more commonly associated with peritonsillar abscess. Streptococcus pyogenes were sensitive to penicillin but all Staphylococcus aureus were resistant to it. This fact should be considered in clinical practice for management of peritonsillar abscess.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21485600

Source DB:  PubMed          Journal:  JNMA J Nepal Med Assoc        ISSN: 0028-2715            Impact factor:   0.406


  6 in total

1.  Risk of Postoperative Bleeding in Tonsillectomy for Peritonsillar Abscess, as Opposed to in Recurrent and Chronic Tonsillitis-A Retrospective Study.

Authors:  David Slouka; Štěpánka Čejková; Jana Hanáková; Petr Hrabačka; Stanislav Kormunda; David Kalfeřt; Alena Skálová; Václav Šimánek; Radek Kucera
Journal:  Int J Environ Res Public Health       Date:  2021-02-17       Impact factor: 3.390

2.  Metallo-β Lactamase Producing Non-Fermentative Gram-Negative Bacilli from Various Clinical Isolates in a Tertiary Care Hospital: A Descriptive Cross-sectional Study.

Authors:  Mahendra Shrestha; Ratna Baral; Lok Bahadur Shrestha
Journal:  JNMA J Nepal Med Assoc       Date:  2021-09-11       Impact factor: 0.556

3.  Antibacterial Derivatives of Ciprofloxacin to Inhibit Growth of Necrotizing Fasciitis Associated Penicillin Resistant Escherichia coli.

Authors:  Ronald Bartzatt; Suat L G Cirillo; Jeffrey D Cirillo
Journal:  J Pharm (Cairo)       Date:  2013-05-02

4.  Epidemiological and Microbiological Aspects of the Peritonsillar Abscess.

Authors:  David Slouka; Jana Hanakova; Tomas Kostlivy; Petr Skopek; Vojtech Kubec; Vaclav Babuska; Ladislav Pecen; Ondřej Topolcan; Radek Kucera
Journal:  Int J Environ Res Public Health       Date:  2020-06-05       Impact factor: 3.390

5.  Bacteriology of peritonsillar abscess: the changing trend and predisposing factors.

Authors:  Yi-Wen Tsai; Yu-Hsi Liu; Hsing-Hao Su
Journal:  Braz J Otorhinolaryngol       Date:  2017-07-17

6.  Staphylococcus aureus in tonsils of patients with recurrent tonsillitis: prevalence, susceptibility profile, and genotypic characterization.

Authors:  Veraluce Paolini Cavalcanti; Leandro Azevedo de Camargo; Fabiano Santana Moura; Edson Júnior de Melo Fernandes; Juliana Lamaro-Cardoso; Carla Afonso da Silva Bitencourt Braga; Maria Cláudia Porfirio André
Journal:  Braz J Infect Dis       Date:  2019-03-06       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.